DROIA
28
50M
18
2.15
4
0.32
1
- Areas of investment
Summary
DROIA appeared to be the VC, which was created in 2011. The main office of represented VC is situated in the Luxembourg. The fund was located in Europe if to be more exact in Luxembourg.
The fund has no specific favorite in a number of founders of portfolio startups. In case when startup counts 3 or 5+ of the founder, the chance for it to get the investment is meager. Among the most successful fund investment fields, there are Therapeutics, Business Development. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Moreover, a startup needs to be at the age of 2-3 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Frontier Medicines, Cyteir Therapeutics, OCTIMET Oncology.
The typical case for the fund is to invest in rounds with 6-7 participants. Despite the DROIA, startups are often financed by Celgene, The Column Group, Venrock. The meaningful sponsors for the fund in investment in the same round are Celgene, Venrock, The Column Group. In the next rounds fund is usually obtained by Celgene, Wellington Management, Venrock.
This organization was formed by Luc Verelst. Besides them, we counted 2 critical employees of this fund in our database.
The top amount of exits for fund were in 2018. Considering the real fund results, this VC is 30 percentage points more often commits exit comparing to other organizations. Deals in the range of 10 - 50 millions dollars are the general things for fund. The fund is constantly included in less than 2 investment rounds annually. The top activity for fund was in 2017. Despite it in 2019 the fund had an activity. This DROIA works on 16 percentage points less the average amount of lead investments comparing to the other organizations.
Investments analytics
Analytics
- Total investments
- 28
- Lead investments
- 4
- Exits
- 1
- Rounds per year
- 2.15
- Follow on index
- 0.32
- Investments by industry
- Biotechnology (24)
- Medical (14)
- Pharmaceutical (14)
- Therapeutics (8)
- Health Care (7) Show 8 more
- Investments by region
-
- United States (20)
- Netherlands (3)
- Denmark (1)
- Belgium (3)
- Peak activity year
- 2020
- Number of Unicorns
- 1
- Number of Decacorns
- 1
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 5
- Group Appearance index
- 0.96
- Avg. company exit year
- 3
- Strategy success index
- 0.40
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Frontier Medicines | 22 Feb 2024 | Biotechnology, Artificial Intelligence, Pharmaceutical | Late Stage Venture | 80M | United States, California, San Francisco |
| Muna Therapeutics | 09 Jul 2021 | Medical, Pharmaceutical, Biopharma | Early Stage Venture | 73M | Hovedstaden, Copenhagen, Denmark |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.